The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Amlodipine/Valsartan/Hydrochlorothiazide Krka 10 mg/160 mg/25 mg film-coated tablets



KRKA, d.d., Novo mestoPA1347/106/004

Main Information

Trade NameAmlodipine/Valsartan/Hydrochlorothiazide Krka 10 mg/160 mg/25 mg film-coated tablets
Active SubstancesAmlodipine
Valsartan
Hydrochlorothiazide
Dosage FormFilm-coated tablet
Licence HolderKRKA, d.d., Novo mesto
Licence NumberPA1347/106/004

Group Information

ATC CodeC09DX01 valsartan, amlodipine and hydrochlorothiazide

Status

License statusAuthorised
Licence Issued16/10/2020
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back